In 1997, Xcelom’s founder was the first to report the existence of cell-free fetal DNA in the blood of pregnant women. After years of dedicated research, methods for the non-invasive screening of fetal chromosomal aneuploidies, were successfully achieved. The clinical performances of the test approaches developed by the research team were subsequently validated and confirmed by a number of international research groups and this formed the basis for many of the non-invasive prenatal testing protocols adopted for clinical use worldwide today. Xcelom is the only licensee of the CUHK technologies in Hong Kong to provide the test.
